Dose finding with escalation with overdose control (EWOC) in cancer clinical trials

Statistical Science

Volumn 25, Issue 2, 2010, Pages 217-226

  Tighiouart, Mourad ^a   Rogatko, André ^b  

^a EMORY UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cancer phase I trials; Dose limiting toxicity; Escalation with overdose control; Optimal Bayesian feasible; Tolerated dose

Indexed keywords

EID: 78650229308     PISSN: 08834237     EISSN: None     Source Type: Journal    
DOI: 10.1214/10-STS333     Document Type: Article

References (38)

1. ADCOCK, C. J. (1997). Sample size determination: A review. The Statistician 46 261-283.
2. BABB, J. and ROGATKO, A. (2004). Contemporary Biostatistical Methods in Clinical Trial. Bayesian Methods for Cancer Phase I Clinical Trials 1-39. Dekker, New York.
3. BABB, J., ROGATKO, A. and ZACKS, S. (1998). Cancer Phase I clinical trials: Efficient dose escalation with overdose control. Stat. Med. 17 1103-1120.
4. BABB, J. S. and ROGATKO, A. (2001). Patient specific dosing in a cancer phase I clinical trial. Statist. Med. 20 2079- 2090.
5. BRAUN, T. M., LEVINE, J. E. and FERRARA, J. L. M. (2003). Determining a maximum tolerated cumulative dose: Dose reassignment within the TITE-CRM. Controlled Clinical Trials 24 669-681.
6. CHENG, J. D., BABB, J. S., LANGER, C., AAMDAL, S., ROBERT, F., ENGELHARDT, L. R., FERNBERG, O., SCHILLER, J., FORSBERG, G., ALPAUGH, R. K.,WEINER, L. M. and ROGATKO, A. (2004). Individualized patient dosing in phase I clinical trials: The role of EWOC in PNU-214936. J. Clin. Oncol. 22 602-609.
7. CHEUNG, Y. K. (2005). Coherence principles in dose-finding studies. Biometrika 92 863-873.
8. CHEUNG, Y. K. and CHAPPELL, R. (2000). Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56 1177-1182.
9. CHU, P. L., LIN, Y. and SHIH, W. J. (2009). Unifying CRM and EWOC designs for phase I cancer clinical trials. J. Statist. Plann. Inference 139 1146-1163.
10. COX, D. R. (1972). Regression models and life-tables. J. R. Stat. Soc. Ser. B Stat. Methodol. 34 187-220.
11. DILLMAN, R. O. and KOZIOL, J. A. (1992). Phase I cancer trials: Limitations and implications. Molecular Biotherapy 4 117-121.
12. FARIES, D. (1994). Practical modifications of the continual reassessment method for phase I cancer clinical trials. J. Biopharm. Statist. 4 147-164.
13. GARRETT-MAYER, E. (2006). The continual reassessment method for dose-finding studies: A tutorial. Clinical Trials 3 57-71.
14. GATSONIS, C. and GREENHOUSE, J. B. (1992). Bayesian methods for phase I clinical trials. Stat. Med. 11 1377-1389.
15. GOODMAN, S. N., ZAHURAK, M. L. and PIANTADOSI, S. (1995). Some practical improvements in the continual reassessment method for phase I studies. Stat. Med. 14 1149- 1161.
16. IVANOVA, A. (2006). Escalation, group and A + B designs for dose-finding trials. Stat. Med. 25 3668-3678.
17. LIN, Y. and SHIH, W. J. (2001). Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics 2 203-215.
18. LUNN, D. J., THOMAS, A., BEST, N. and SPIEGELHALTER, D. (2000). WinBUGS-a Bayesian modelling framework: Concepts, structure, and extensibility. Statist. Comput. 10 325-337.
19. MOLLER, S. (1995). An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Stat. Med. 14 911-922.
20. NCI (2003). Common toxicity criteria for adverse events v3.0 (CTCAE).
21. O'QUIGLEY, J., PEPE, M. and FISHER, L. (1990). Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 46 33-48.
22. O'QUIGLEY, J., SHEN, L. Z. and GAMST, A. (1999). Twosample continual reassessment method. J. Biopharm. Statist. 9 17-44.
23. PIANTADOSI, S., FISHER, J. D. andGROSSMAN, S. (1998). Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother. Pharmacol. 41 429-436.
24. ROBERTS, T. G. J., GOULART, B., SQUITIERI, L., STALLINGS, S. C., HALPERN, E. F., CHABNER, B. A., GAZELLE, G. S., FINKELSTEIN, S. N. and CLARK, J. W. (2004). Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. J. Amer. Med. Assoc. 292 2130-2140.
25. ROGATKO, A., GHOSH, P., VIDAKOVIC, B. and TIGHIOUART, M. (2008). Patient-specific dose adjustment in the cancer clinical trial setting. Pharm. Med. 22 345-350.
26. ROGATKO, A., TIGHIOUART, M. andXU, Z. (2005). EWOC 2.1 application software. Available at http://sisyphus.emory.edu/software.php.
27. ROSENBERGER, W. F. and HAINES, L. M. (2002). Competing designs for phase I clinical trials: A review. Stat. Med. 21 2757-2770.
28. STORER, B. E. (2001). An evaluation of phase I clinical trial designs in the continuous dose-response setting. Stat. Med. 20 2399-2408.
29. TIGHIOUART, M. and ROGATKO, A. (2006). Dose Finding in Drug Development. Dose Finding in Oncology-Parametric Methods 59-72. Springer, New York.
30. TIGHIOUART, M. and ROGATKO, A. (2006). Statistical Methods for Dose-Finding Experiments. Dose Escalation with Overdose Control 173-188. Wiley, New York.
31. TIGHIOUART, M., ROGATKO, A. and BABB, J. S. (2005). Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Stat. Med. 24 2183- 2196.
32. TIGHIOUART, M., ROGATKO, A. and XU, Z. (2007). Incorporating patient's characteristics in cancer phase I clinical trials using escalation with overdose control. In Joint Statistical Meetings. Salt Lake City.
33. TING, N. (2006). Dose Finding in Drug Development. Springer, New York.
34. WHITEHEAD, J. (1997). Bayesian decision procedures with application to dose-finding studies. Int. J. Pharm. Med. 11 201-208.
35. XU, Z., TIGHIOUART, M. andROGATKO, A. (2007). EWOC 2.1: Interactive software for dose escalation in cancer phase I clinical trials. Drug Inform. J. 41 221-228.
36. ZACKS, S., ROGATKO, A. and BABB, J. (1998). Optimal Bayesian-feasibile dose escalation for cancer phase I trials. Statist. Probab. Lett. 38 215-220.
37. ZOHAR, S. andCHEVRET, S. (2001). The continual reassessment method: Comparison of Bayesian stopping rules for dose-ranging studies. Stat. Med. 20 2827-2843.
38. ZOHAR, S., LATOUCHE, A., TACONNER, M. and CHEVRET, S. (2003). Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules. Comput. Methods Programs Biomed. 72 117-125.